PWPS
SUPN icon

Pinnacle Wealth Planning Services’s Supernus Pharmaceuticals SUPN Stock Holding History

Pinnacle Wealth Planning Services’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$161K Buy
3,107
+24
+0.8% +$1.22K 0.02% 561
2025
Q4 		$153K Buy
+3,083
New +$150K 0.02% 578
2021
Q1 		– Sell
-51
Closed -$2K – 1743
2020
Q4 		$2K Buy
+51
New +$1.1K ﹤0.01% 1982

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pinnacle Wealth Planning Services's SUPN Position: Q1 2026 in Review

Pinnacle Wealth Planning Services increased its Supernus Pharmaceuticals (SUPN) stake by 0.78% in Q1 2026, buying an estimated $1.22K and bringing the position to 3,107 shares worth $161K. The position accounts for 0.02% of the portfolio, ranked #561.

Pinnacle Wealth Planning Services first reported a position in SUPN in Q4 2020 and has held it in 3 quarters since. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Pinnacle Wealth Planning Services held 3,107 shares of Supernus Pharmaceuticals worth $161K as of Q1 2026.
  • Pinnacle Wealth Planning Services bought 24 Supernus Pharmaceuticals shares in Q1 2026, an estimated $1.22K.
  • Supernus Pharmaceuticals made up 0.02% of Pinnacle Wealth Planning Services's portfolio in Q1 2026, its #561 holding.
  • Pinnacle Wealth Planning Services first reported a position in Supernus Pharmaceuticals in Q4 2020 and has held it in 3 quarters since.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Pinnacle Wealth Planning Services's 13F filing for Q1 2026, filed 11 May 2026.